Press releases
GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)
GlaxoSmithKline plc (GSK) announced today that the European Commission has granted marketing authorisation for Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine) for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
GSK announced today that the U.S. FDA has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy.
Children in Ghana to be vaccinated against diarrhoeal disease with the introduction of GSK’s Rotarix™ vaccine
GSK welcomes today’s GAVI announcement that GSK’s rotavirus vaccine, Rotarix™, will be introduced into the newly started national vaccination programme in Ghana.
GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry
GSK and the University of Nottingham today formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.
Results announcement for the first quarter 2012
- Sales growth of +2% CER - Further R&D delivery, operational leverage and continued returns to shareholders - Core EPS 27.3p (+7%), dividend up 6% to 17p
GlaxoSmithKline reaches agreement to divest non-core over-the-counter (OTC) brands in international markets for £164 million
GlaxoSmithKline Plc (GSK) today announced that it has reached agreement to divest the previously identified non-core OTC brands in its international markets to Aspen Pharmacare Holdings Limited (Aspen) for £164 million in cash.
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
GlaxoSmithKline plc today confirms that it made an offer to the Board of Directors of Human Genome Sciences on 11th April proposing to acquire all of the outstanding shares of HGS for US$13.00 per share in cash, representing a 81 percent premium to yesterday’s closing share price.
GSK provides update on corporate responsibility commitments in 2011 report
GSK has today published its Corporate Responsibility Report, in which the company reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
GSK today announced that topline results have been received from seven of the eight ‘Harmony’ Phase III studies investigating the use of albiglutide in type 2 diabetes. Albiglutide is an investigational once weekly glucagon-like peptide-1 (GLP-1) agonist.
GlaxoSmithKline to increase its ownership in Theravance
GSK and Theravance, Inc. announced they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will acquire, 10,000,000 shares of Theravance common stock at a price of $21.2887 per share, for a total investment of $212,887,000.
